» Articles » PMID: 18430864

Effect of Cysteine Mutagenesis on the Function and Disulfide Bond Formation of Human ABCG2

Overview
Specialty Pharmacology
Date 2008 Apr 24
PMID 18430864
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

ABCG2 is a member of the ATP-binding cassette (ABC) transporter superfamily. Its overexpression causes multidrug resistance in cancer chemotherapy. Based on its apparent half size in sequence when compared with other traditional ABC transporters, ABCG2 has been thought to exist and function as a homodimer linked by intermolecular disulfide bonds. However, recent evidence suggests that ABCG2 may exist as a higher form of oligomers due to noncovalent interactions. In this study, we attempted to create a cysless mutant ABCG2 as a tool for further characterization of this molecule. However, we found that the cysless mutant ABCG2 is well expressed but not functional. Mapping of the cysteine residues showed that three cysteine residues (Cys284, Cys374, and Cys438) are required concurrently for the function of ABCG2 and potentially for intramolecular disulfide bond formation. We also found that the cysteine residues (Cys592, Cys603, and Cys608) in the third extracellular loop are involved in forming intermolecular disulfide bonds and that mutation of these residues does not affect the expression or drug transport activity of human ABCG2. Thus, we conclude that Cys284, Cys374, and Cys438, which may be involved in intramolecular disulfide bond formation, are concurrently required for ABCG2 function, whereas Cys592, Cys603, and Cys608, potentially involved in intermolecular disulfide bond formation, are not required.

Citing Articles

A Structure-Based View on ABC-Transporter Linked to Multidrug Resistance.

Huang J, Ecker G Molecules. 2023; 28(2).

PMID: 36677553 PMC: 9862083. DOI: 10.3390/molecules28020495.


The first intracellular loop is essential for the catalytic cycle of the human ABCG2 multidrug resistance transporter.

Khunweeraphong N, Kuchler K FEBS Lett. 2020; 594(23):4059-4075.

PMID: 33169382 PMC: 7756363. DOI: 10.1002/1873-3468.13994.


3D structure of the transporter ABCG2-What's new?.

Eckenstaler R, Benndorf R Br J Pharmacol. 2020; 177(7):1485-1496.

PMID: 31985041 PMC: 7060357. DOI: 10.1111/bph.14991.


Residues contributing to drug transport by ABCG2 are localised to multiple drug-binding pockets.

Cox M, Kapoor P, Briggs D, Kerr I Biochem J. 2018; 475(9):1553-1567.

PMID: 29661915 PMC: 5934980. DOI: 10.1042/BCJ20170923.


Redox Paradox: A Novel Approach to Therapeutics-Resistant Cancer.

Chaiswing L, St Clair W, St Clair D Antioxid Redox Signal. 2018; 29(13):1237-1272.

PMID: 29325444 PMC: 6157438. DOI: 10.1089/ars.2017.7485.


References
1.
Litman T, Jensen U, Hansen A, Zhan Z, Fetsch P, Abati A . Use of peptide antibodies to probe for the mitoxantrone resistance-associated protein MXR/BCRP/ABCP/ABCG2. Biochim Biophys Acta. 2002; 1565(1):6-16. DOI: 10.1016/s0005-2736(02)00492-3. View

2.
Xu J, Peng H, Zhang J . Human multidrug transporter ABCG2, a target for sensitizing drug resistance in cancer chemotherapy. Curr Med Chem. 2007; 14(6):689-701. DOI: 10.2174/092986707780059580. View

3.
Bhatia A, Schafer H, Hrycyna C . Oligomerization of the human ABC transporter ABCG2: evaluation of the native protein and chimeric dimers. Biochemistry. 2005; 44(32):10893-904. DOI: 10.1021/bi0503807. View

4.
Yang Y, Chen Q, Zhang J . Structural and functional consequences of mutating cysteine residues in the amino terminus of human multidrug resistance-associated protein 1. J Biol Chem. 2002; 277(46):44268-77. DOI: 10.1074/jbc.M207003200. View

5.
McDevitt C, Collins R, Conway M, Modok S, Storm J, Kerr I . Purification and 3D structural analysis of oligomeric human multidrug transporter ABCG2. Structure. 2006; 14(11):1623-32. DOI: 10.1016/j.str.2006.08.014. View